Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165564737> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3165564737 endingPage "1644" @default.
- W3165564737 startingPage "1639" @default.
- W3165564737 abstract "Background: The side effects of conditioning regimens on the success rate of allogeneic transplantation around the world have been challenging. In this study, we aimed to investigate the side effect of Bu/Cy and Bu/Flu regimens on our patients who underwent allogeneic bone marrow transplantation. Methods: We analyzed 180 patients receiving bone marrow transplantation in Taleghani Hospital, in Tehran, Iran between April 2016 and December 2019. Patients in group A received a combination of intravenous busulfan 0.8 mg/kg QID over two hours for 4 consecutive days (12.8 mg/kg in total)(Savani et al., 2006) and cyclophosphamide 60 mg/kg per day for two consecutive days. Patients in group B received busulfan the same as the first group in combination with fludarabine equal to 40 mg/m² per day. Patients were followed up at regular intervals up to two years after transplantation. Result: Various items were evaluated for patients, including cardiopulmonary function, psychological disorders, GVHD, and endocrine disorders such as hypothyroidism, fertility, or gonad dysfunction. Primary hypothyroidism developed in 13.3% and 11.1% of the Bu/Cy and Bu/Flu groups, respectively (p=0.230). None of the patients in either group experienced infertility or gonad dysfunction. In group A versus group B, pulmonary diseases were detected in 4.4% versus 6.6% of BMT recipients, respectively (p = 0.223). In both groups, mitral and tricuspid regurgitation were observed in patients (8.9% vs. 11.1%; p = 0.189). Incidence of Psychological disorders was no significant difference between the two groups. 32.2% of group A versus 34.45% of group B had skin and liver GVHD, respectively (p = 0.235). Conclusion: The therapeutic-related adverse effects of the two conditioning regimens in patients who underwent allogeneic bone marrow transplant were almost similar. To improve quality of life and overall survival among BMT patients, careful evaluation of treatment-related complications should be part of the regular follow-up of them." @default.
- W3165564737 created "2021-06-07" @default.
- W3165564737 creator A5010862393 @default.
- W3165564737 creator A5013410259 @default.
- W3165564737 creator A5046050496 @default.
- W3165564737 creator A5047549043 @default.
- W3165564737 creator A5072547331 @default.
- W3165564737 creator A5085453372 @default.
- W3165564737 date "2021-05-01" @default.
- W3165564737 modified "2023-09-26" @default.
- W3165564737 title "Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation" @default.
- W3165564737 doi "https://doi.org/10.31557/apjcp.2021.22.5.1639" @default.
- W3165564737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8408385" @default.
- W3165564737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34048196" @default.
- W3165564737 hasPublicationYear "2021" @default.
- W3165564737 type Work @default.
- W3165564737 sameAs 3165564737 @default.
- W3165564737 citedByCount "2" @default.
- W3165564737 countsByYear W31655647372022 @default.
- W3165564737 countsByYear W31655647372023 @default.
- W3165564737 crossrefType "journal-article" @default.
- W3165564737 hasAuthorship W3165564737A5010862393 @default.
- W3165564737 hasAuthorship W3165564737A5013410259 @default.
- W3165564737 hasAuthorship W3165564737A5046050496 @default.
- W3165564737 hasAuthorship W3165564737A5047549043 @default.
- W3165564737 hasAuthorship W3165564737A5072547331 @default.
- W3165564737 hasAuthorship W3165564737A5085453372 @default.
- W3165564737 hasBestOaLocation W31655647371 @default.
- W3165564737 hasConcept C126322002 @default.
- W3165564737 hasConcept C141071460 @default.
- W3165564737 hasConcept C2776694085 @default.
- W3165564737 hasConcept C2776755627 @default.
- W3165564737 hasConcept C2779263901 @default.
- W3165564737 hasConcept C2780007613 @default.
- W3165564737 hasConcept C2780611847 @default.
- W3165564737 hasConcept C2911091166 @default.
- W3165564737 hasConcept C71924100 @default.
- W3165564737 hasConcept C90924648 @default.
- W3165564737 hasConceptScore W3165564737C126322002 @default.
- W3165564737 hasConceptScore W3165564737C141071460 @default.
- W3165564737 hasConceptScore W3165564737C2776694085 @default.
- W3165564737 hasConceptScore W3165564737C2776755627 @default.
- W3165564737 hasConceptScore W3165564737C2779263901 @default.
- W3165564737 hasConceptScore W3165564737C2780007613 @default.
- W3165564737 hasConceptScore W3165564737C2780611847 @default.
- W3165564737 hasConceptScore W3165564737C2911091166 @default.
- W3165564737 hasConceptScore W3165564737C71924100 @default.
- W3165564737 hasConceptScore W3165564737C90924648 @default.
- W3165564737 hasIssue "5" @default.
- W3165564737 hasLocation W31655647371 @default.
- W3165564737 hasLocation W31655647372 @default.
- W3165564737 hasOpenAccess W3165564737 @default.
- W3165564737 hasPrimaryLocation W31655647371 @default.
- W3165564737 hasRelatedWork W1990247501 @default.
- W3165564737 hasRelatedWork W2000025145 @default.
- W3165564737 hasRelatedWork W2098356351 @default.
- W3165564737 hasRelatedWork W2493352844 @default.
- W3165564737 hasRelatedWork W2517815005 @default.
- W3165564737 hasRelatedWork W2560664961 @default.
- W3165564737 hasRelatedWork W2589386091 @default.
- W3165564737 hasRelatedWork W2979908979 @default.
- W3165564737 hasRelatedWork W3173436519 @default.
- W3165564737 hasRelatedWork W4386189998 @default.
- W3165564737 hasVolume "22" @default.
- W3165564737 isParatext "false" @default.
- W3165564737 isRetracted "false" @default.
- W3165564737 magId "3165564737" @default.
- W3165564737 workType "article" @default.